{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T10:23:03Z","timestamp":1782814983930,"version":"3.54.5"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,1,25]],"date-time":"2025-01-25T00:00:00Z","timestamp":1737763200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,25]],"date-time":"2025-01-25T00:00:00Z","timestamp":1737763200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"DOI":"10.1007\/s12094-025-03845-w","type":"journal-article","created":{"date-parts":[[2025,1,25]],"date-time":"2025-01-25T10:53:15Z","timestamp":1737802395000},"page":"3144-3153","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["SABR tolerance after prostatectomy: pushing the boundaries of ultrahypofractionation"],"prefix":"10.1007","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5566-0493","authenticated-orcid":false,"given":"Angel","family":"Montero","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ovidio","family":"Hernando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mercedes","family":"L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeannette","family":"Valero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0130-878X","authenticated-orcid":false,"given":"Raquel","family":"Ci\u00e9rvide","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilio","family":"S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Prado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena B.","family":"Zobec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5118-1513","authenticated-orcid":false,"given":"Xin","family":"Chen-Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"\u00c1lvarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariola","family":"Garc\u00eda-Aranda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leyre","family":"Alonso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"Alonso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Fern\u00e1ndez-Let\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Rubio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,25]]},"reference":[{"key":"3845_CR1","unstructured":"ECIS - European Cancer Information System, From: https:\/\/ecis.jrc.ec.europa.eu, \u00a9 European Union, 2023."},{"issue":"23","key":"3845_CR2","doi-asserted-by":"publisher","first-page":"8754","DOI":"10.1002\/cam4.3482","volume":"9","author":"B Kaps","year":"2020","unstructured":"Kaps B, Leapman M, An Y. Trends in prostatectomy utilization: increasing upfront prostatectomy and postprostatectomy radiotherapy for high-risk prostate cancer. Cancer Med. 2020;9(23):8754\u201364. https:\/\/doi.org\/10.1002\/cam4.3482.","journal-title":"Cancer Med"},{"key":"3845_CR3","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.urolonc.2006.06.003","volume":"25","author":"GP Swanson","year":"2007","unstructured":"Swanson GP, Riggs M, Hermans M. Pathologic findings at radical prostatectomy: risk factors for failure and death. UrolOncol. 2007;25:110\u20134. https:\/\/doi.org\/10.1016\/j.urolonc.2006.06.003.","journal-title":"UrolOncol"},{"issue":"3","key":"3845_CR4","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.eururo.2011.10.010","volume":"61","author":"AJ Stephenson","year":"2012","unstructured":"Stephenson AJ, Bolla M, Briganti A, Cozzarini C, Moul JW, Roach M III, et al. Postoperative radiation therapy for pathologically advanced prostate cancer after radical prostatectomy. Eur Urol. 2012;61(3):443\u201351. https:\/\/doi.org\/10.1016\/j.eururo.2011.10.010.","journal-title":"Eur Urol"},{"issue":"2","key":"3845_CR5","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.eururo.2014.03.011","volume":"66","author":"T Wiegel","year":"2014","unstructured":"Wiegel T, Bartkowiak D, Bottke D, Bronner C, Steiner U, Siegmann A, et al. Adjuvant radiotherapy versus wait-and-see after radical prostatectomy: 10-year follow-up of the ARO 96\u201302\/AUO AP 09\/95 trial. EurUrol. 2014;66(2):243\u201350. https:\/\/doi.org\/10.1016\/j.eururo.2014.03.011.","journal-title":"EurUrol."},{"issue":"9858","key":"3845_CR6","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1016\/S0140-6736(12)61253-7","volume":"380","author":"M Bolla","year":"2012","unstructured":"Bolla M, van Poppel H, Tombal B, Vekemans K, Da Pozzo L, de Reijke TM, et al. Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911). Lancet. 2012;380(9858):2018\u201327. https:\/\/doi.org\/10.1016\/S0140-6736(12)61253-7.","journal-title":"Lancet"},{"issue":"10260","key":"3845_CR7","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1016\/S0140-6736(20)31952-8","volume":"396","author":"CL Vale","year":"2020","unstructured":"Vale CL, Fisher D, Kneebone A, Parker C, Pearse M, Richaud P, et al. Adjuvant or early salvage radiotherapy for the treatment of localised and locally advanced prostate cancer: a prospectively planned systematic review and meta-analysis of aggregate data. Lancet. 2020;396(10260):1422\u201331. https:\/\/doi.org\/10.1016\/S0140-6736(20)31952-8.","journal-title":"Lancet"},{"issue":"10260","key":"3845_CR8","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1016\/S0140-6736(20)31553-1","volume":"396","author":"CC Parker","year":"2020","unstructured":"Parker CC, Clarke NW, Cook AD, Kynaston HG, Petersen PM, Catton C, et al. Timing of radiotherapy after radical prostatectomy (RADICALS-RT): a randomised, controlled phase 3 trial. Lancet. 2020;396(10260):1413\u201321. https:\/\/doi.org\/10.1016\/S0140-6736(20)31553-1.","journal-title":"Lancet"},{"issue":"10","key":"3845_CR9","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1016\/S1470-2045(20)30454-X","volume":"21","author":"P Sargos","year":"2020","unstructured":"Sargos P, Chabaud S, Latorzeff I, Magn\u00e9 N, Benyoucef A, Supiot S, et al. Adjuvant radiotherapy versus early salvage radiotherapy plus short-term androgen deprivation therapy in men with localised prostate cancer after radical prostatectomy (GETUG-AFU 17): a randomised, phase 3 trial. Lancet Oncol. 2020;21(10):1341\u201352. https:\/\/doi.org\/10.1016\/S1470-2045(20)30454-X.","journal-title":"Lancet Oncol"},{"issue":"10","key":"3845_CR10","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1016\/S1470-2045(20)30456-3","volume":"21","author":"A Kneebone","year":"2020","unstructured":"Kneebone A, Fraser-Browne C, Duchesne GM, Fisher R, Frydenberg M, Herschtal A, et al. Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG 08.03\/ANZUP RAVES): a randomised, controlled, phase 3, non-inferiority trial. Lancet Oncol. 2020;21(10):1331\u201340. https:\/\/doi.org\/10.1016\/S1470-2045(20)30456-3.","journal-title":"Lancet Oncol"},{"issue":"6","key":"3845_CR11","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.prro.2018.08.002","volume":"8","author":"SC Morgan","year":"2018","unstructured":"Morgan SC, Hoffman K, Loblaw DA, Buyyounouski MK, Patton C, Barocas D, et al. Hypofractionated radiation therapy for localized prostate cancer: executive summary of an ASTRO, ASCO, and AUA evidence-based guideline. Pract Radiat Oncol. 2018;8(6):354\u201360. https:\/\/doi.org\/10.1016\/j.prro.2018.08.002.","journal-title":"Pract Radiat Oncol"},{"issue":"2","key":"3845_CR12","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.ijrobp.2009.02.006","volume":"76","author":"JM Michalski","year":"2010","unstructured":"Michalski JM, Lawton C, El Naqa I, Ritter M, O\u2019Meara E, Seider MJ, et al. Development of RTOG consensus guidelines for the definition of the clinical target volume for postoperative conformal radiation therapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2010;76(2):361\u20138. https:\/\/doi.org\/10.1016\/j.ijrobp.2009.02.006.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"10338","key":"3845_CR13","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.1016\/S0140-6736(21)01790-6","volume":"399","author":"A Pollack","year":"2022","unstructured":"Pollack A, Karrison TG, Balogh AG, Gomella LG, Low DA, Bruner DW, et al. The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy (NRG Oncology\/RTOG 0534 SPPORT): an international, multicenter, randomized phase 3 trial. Lancet. 2022;399(10338):1886\u2013901. https:\/\/doi.org\/10.1016\/S0140-6736(21)01790-6.","journal-title":"Lancet"},{"key":"3845_CR14","unstructured":"Cancer Institute N. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 2017. Available at: https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_5x7.pdf."},{"issue":"6","key":"3845_CR15","doi-asserted-by":"publisher","first-page":"2708","DOI":"10.1016\/j.juro.2009.08.027","volume":"182","author":"SA Boorjian","year":"2009","unstructured":"Boorjian SA, Karnes RJ, Crispen PL, Rangel LJ, Bergstralh EJ, Blute ML. Radiation therapy after radical prostatectomy: impact on metastasis and survival. J Urol. 2009;182(6):2708\u201314. https:\/\/doi.org\/10.1016\/j.juro.2009.08.027.","journal-title":"J Urol"},{"issue":"23","key":"3845_CR16","doi-asserted-by":"publisher","first-page":"2760","DOI":"10.1001\/jama.299.23.2760","volume":"299","author":"BJ Trock","year":"2008","unstructured":"Trock BJ, Han M, Freedland SJ, Humphreys EB, DeWeese TL, Partin AW, et al. Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy. JAMA. 2008;299(23):2760\u20139. https:\/\/doi.org\/10.1001\/jama.299.23.2760.","journal-title":"JAMA"},{"key":"3845_CR17","unstructured":"European Association of Urology (EAU) Guidelines for Prostate Cancer. Saint-\u00c9tienne, Auvergne-Rh\u00f4ne-Alpes: EAU; 2020.AUA. Adjuvant and Salvage Radiotherapy After Prostatectomy. ASTRO\/AUA Guideline. Arlington, Virginia: AUA; 2020."},{"issue":"10260","key":"3845_CR18","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1016\/S0140-6736(20)31957-7","volume":"396","author":"D Tilki","year":"2020","unstructured":"Tilki D, D\u2019Amico AV. Timing of radiotherapy after radical prostatectomy. Lancet. 2020;396(10260):1374\u20135. https:\/\/doi.org\/10.1016\/S0140-6736(20)31957-7.","journal-title":"Lancet"},{"issue":"2","key":"3845_CR19","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.eururo.2020.09.042","volume":"79","author":"N Mottet","year":"2021","unstructured":"Mottet N, van den Bergh RCN, Briers E, Van den Broeck T, Cumberbatch MG, De Santis M, et al. EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer-2020 update: part 1\u2014screening, diagnosis, and local treatment with curative intent. Eur Urol. 2021;79(2):243\u201362. https:\/\/doi.org\/10.1016\/j.eururo.2020.09.042.","journal-title":"Eur Urol"},{"issue":"22","key":"3845_CR20","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.euros.2020.10.001","volume":"23","author":"S Mahase","year":"2020","unstructured":"Mahase S, Nagar H. Hypofractionated postoperative radiotherapy for prostate cancer: is the field ready yet? Eur Urol Open Sci. 2020;23(22):9\u201316. https:\/\/doi.org\/10.1016\/j.euros.2020.10.001.","journal-title":"Eur Urol Open Sci"},{"issue":"3","key":"3845_CR21","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1007\/s00345-015-1613-5","volume":"34","author":"B Detti","year":"2016","unstructured":"Detti B, Bonomo P, Masi L, Doro R, Cipressi S, Iermano C, et al. CyberKnife stereotactic radiotherapy for isolated recurrence in the prostatic bed. World J Urol. 2016;34(3):311\u20137. https:\/\/doi.org\/10.1007\/s00345-015-1613-5.","journal-title":"World J Urol"},{"issue":"1","key":"3845_CR22","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.ijrobp.2018.12.047","volume":"104","author":"LK Ballas","year":"2019","unstructured":"Ballas LK, Luo C, Chung E, Kishan AU, Shuryak I, Quinn DI, et al. Phase 1 trial of SBRT to the prostate fossa after prostatectomy. Int J Radiat Oncol Biol Phys. 2019;104(1):50\u201360. https:\/\/doi.org\/10.1016\/j.ijrobp.2018.12.047.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"3845_CR23","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.ijrobp.2019.11.005","volume":"106","author":"S Sampath","year":"2020","unstructured":"Sampath S, Frankel P, Vecchio BD, Ruel N, Yuh B, Liu A, et al. Stereotactic body radiation therapy to the prostate bed: results of a phase 1 dose-escalation trial. Int J Radiat Oncol Biol Phys. 2020;106(3):537\u201345. https:\/\/doi.org\/10.1016\/j.ijrobp.2019.11.005.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"12","key":"3845_CR24","doi-asserted-by":"publisher","first-page":"9349","DOI":"10.3390\/curroncol29120733","volume":"29","author":"R Lucchini","year":"2022","unstructured":"Lucchini R, Franzese C, Vukcaj S, Purrello G, Panizza D, Faccenda V, et al. Acute toxicity and quality of life in a post-prostatectomy ablative radiation therapy (POPART) multicentric trial. Curr Oncol. 2022;29(12):9349\u201356. https:\/\/doi.org\/10.3390\/curroncol29120733.","journal-title":"Curr Oncol"},{"issue":"2","key":"3845_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.adro.2022.101143","volume":"8","author":"BS Laughlin","year":"2022","unstructured":"Laughlin BS, Voss MM, Toesca DA, Daniels T, Golafshar MA, Keole SR, et al. Preliminary analysis of a phase II trial of stereotactic body radiation therapy for prostate cancer with high-risk features after radical prostatectomy. Adv Radiat Oncol. 2022;8(2): 101143. https:\/\/doi.org\/10.1016\/j.adro.2022.101143.","journal-title":"Adv Radiat Oncol"},{"issue":"1","key":"3845_CR26","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.ijrobp.2022.08.041","volume":"115","author":"TM Ma","year":"2023","unstructured":"Ma TM, Ballas LK, Wilhalme H, Sachdeva A, Chong N, Sharma S, et al. Quality-of-life outcomes and toxicity profile among patients with localized prostate cancer after radical prostatectomy treated with stereotactic body radiation: the SCIMITAR multicenter phase 2 trial. Int J Radiat Oncol Biol Phys. 2023;115(1):142\u201352. https:\/\/doi.org\/10.1016\/j.ijrobp.2022.08.041.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"44","key":"3845_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctro.2023.100704","volume":"25","author":"F Ferrario","year":"2023","unstructured":"Ferrario F, Franzese C, Faccenda V, Vukcaj S, Belmonte M, Lucchini R, et al. Toxicity profile and patient-reported outcomes following salvage stereotactic ablative radiation therapy to the prostate bed: the POPART multicentric prospective study. Clin Transl Radiat Oncol. 2023;25(44): 100704. https:\/\/doi.org\/10.1016\/j.ctro.2023.100704.","journal-title":"Clin Transl Radiat Oncol"},{"issue":"2","key":"3845_CR28","doi-asserted-by":"publisher","first-page":"S146","DOI":"10.1016\/j.ijrobp.2024.07.2155.5los","volume":"120","author":"CL Tseng","year":"2024","unstructured":"Tseng CL, Vesprini D, Davidson MTM, Liu SK, Detsky J, Cheung P, et al. Post-prostatectomy linac based ultrahypofractionated radiotherapy for patients with localized prostate cancer toxicity and quality-of life results from a prospective trial. IN J Radiat Oncol Biol Phys. 2024;120(2):S146-147. https:\/\/doi.org\/10.1016\/j.ijrobp.2024.07.2155.5los.","journal-title":"IN J Radiat Oncol Biol Phys"},{"key":"3845_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctro.2023.100638","volume":"41","author":"A Dal Pra","year":"2023","unstructured":"Dal Pra A, Dirix P, Khoo V, Carrie C, Cozzarini C, Fonteyne V, et al. ESTRO ACROP guideline on prostate bed delineation for postoperative radiotherapy in prostate cancer. Clin Transl Radiat Oncol. 2023;41: 100638. https:\/\/doi.org\/10.1016\/j.ctro.2023.100638.","journal-title":"Clin Transl Radiat Oncol"},{"key":"3845_CR30","volume":"40","author":"A Sujenthiran","year":"2023","unstructured":"Sujenthiran A, Parry MG, Dodkins J, Nossiter J, Morris M, Berry B, et al. Treatment-related toxicity using prostate bed versus prostate bed and pelvic lymph node radiation therapy following radical prostatectomy: a national population-based study. Clin Transl Radiat Oncol. 2023;40: 100622.","journal-title":"Clin Transl Radiat Oncol"},{"key":"3845_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2023.09.053","author":"O Mohamad","year":"2023","unstructured":"Mohamad O, Zamboglou C, Zilli T, et al. Safety of ultra-hypofractionated pelvic nodal irradiation in the definitive management of prostate cancer: systematic review and meta-analysis. Int J Radiat Oncol Biol Phys. 2023. https:\/\/doi.org\/10.1016\/j.ijrobp.2023.09.053.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"7","key":"3845_CR32","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1007\/s12094-020-02543-z","volume":"23","author":"J Valero","year":"2021","unstructured":"Valero J, Montero A, Hernando O, Izquierdo M, S\u00e1nchez E, Garc\u00eda-Aranda M, et al. Moderate hypofractionated post-prostatectomy radiation therapy is feasible and well tolerated: experience from a single tertiary cancer centre. Clin Transl Oncol. 2021;23(7):1452\u201362. https:\/\/doi.org\/10.1007\/s12094-020-02543-z.","journal-title":"Clin Transl Oncol"},{"issue":"4","key":"3845_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2024.102102","volume":"22","author":"A Castelluccia","year":"2024","unstructured":"Castelluccia A, Tramacere F, Colciago RR, Borgia M, Sallustio A, Proto T, et al. 10-yr results of moderately hypofractionated postoperative radiotherapy for prostate cancer focused on treatment related toxicity. Clin Genitourin Cancer. 2024;22(4): 102102. https:\/\/doi.org\/10.1016\/j.clgc.2024.102102.","journal-title":"Clin Genitourin Cancer"},{"key":"3845_CR34","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.radonc.2022.03.006","volume":"171","author":"GA Viani","year":"2022","unstructured":"Viani GA, Gouveia AG, Leite ETT, Moraes FY. Moderate hypofractionation for salvage radiotherapy (HYPO-SRT) in patients with biochemical recurrence after prostatectomy: a cohort study with meta-analysis. Radiother Oncol. 2022;171:7\u201313. https:\/\/doi.org\/10.1016\/j.radonc.2022.03.006.","journal-title":"Radiother Oncol"},{"issue":"1","key":"3845_CR35","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.ijrobp.2023.11.048","volume":"119","author":"A Alexander","year":"2024","unstructured":"Alexander A, Gagne I, Bahl G, Kim D, Mestrovic A, Ye A, et al. Late toxicity of prostate ultrahypofractionated radiation therapy compared with moderate hypofractionation in a randomized trial. Int J Radiat Oncol Biol Phys. 2024;119(1):110\u20138. https:\/\/doi.org\/10.1016\/j.ijrobp.2023.11.048.","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-025-03845-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-025-03845-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-025-03845-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T14:35:32Z","timestamp":1750343732000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-025-03845-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,25]]},"references-count":35,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,7]]}},"alternative-id":["3845"],"URL":"https:\/\/doi.org\/10.1007\/s12094-025-03845-w","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,25]]},"assertion":[{"value":"5 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All the authors declare no conflict of interest regarding any aspect of the manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed were in accordance with the ethical standards of the institutional research committee and with the Helsinki Declaration and informed consent was obtained from all individual participants included in this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and informed consent"}}]}}